484 results about "Atheromatosis" patented technology

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The present invention discloses a pharmaceutical composition comprising a circular RNA and a drug delivery carrier. Compared with traditional linear 1 * siRNA and annular 1 * siRNA, the number of repeated series connection of positive-sense strands is increased to include but not limited to two or more, it is accidentally found that the silence effect is remarkably enhanced, the expression level of the PCSK9 gene can be remarkably reduced, and degradation of mRNA of PCSK9 protein is mediated. The nano-particles are used for delivering oligonucleotide, so that the stability is improved, the immunogenicity is reduced, the effects of lowering cholesterol, reducing aortic plaque load and resisting atherosclerosis are improved, and the nano-particles are safe and free of obvious liver and kidney toxicity and have a wide application prospect in the aspect of preparing medicines for treating hypercholesterolemia and coronary heart disease.

This disclosure relates to systems, methods, and devices for plaque analysis, vessel and fluid flow analysis, and / or risk determination or prediction thereof. Some embodiments relate to determining fractional flow reserve (FFR) values. Some embodiments relate to determining FFR values using 3D-printed models. Some embodiments relate to identifying thin cap fibroatheroma based on analysis of computed tomography (CT) imaging. Some embodiments relate adjusting calcified plaque thresholds for CT images to address effects of calcium blooming.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

Provided is a pharmaceutical composition, comprising a circular RNA and a drug delivery carrier. It is surprisingly found that compared with conventional linear 1 x siRNAs and circular 1 x siRNAs, increasing the number of tandem repeats in the sense strand to two or more significantly enhances the silencing effect, significantly reduces the expression level of the PCSK9 gene, and mediates the degradation of the PCSK9 protein mRNA. The use of nano-particles for delivering oligonucleotides features improved stability, reduced immunogenicity, improved cholesterol-lowering, aortic plaque load-reducing and anti-atherosclerotic effects, good safety, no significant liver and kidney toxicity, and therefore good prospects in preparing medicaments for treating hypercholesterolemia and a coronary heart disease.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The invention relates to the technical field of biological medicines, and provides a self-assembled polypeptide-rhein conjugate, a preparation as well as a preparation method and application of the self-assembled polypeptide-rhein conjugate. The sequence of the MMP-9 responsive self-assembled polypeptide-rhein conjugate is Rhein-GFFPLGLAGACE, and the MMP-9 responsive self-assembled polypeptide-rhein conjugate can respond to abnormally activated MMP-9 in atherosclerotic plaque and is self-assembled into a stable nanofiber structure in situ at a diseased region; the anti-inflammatory and anti-oxidation functions of rhein in the conjugate are remarkable, but the water solubility and oral bioavailability are low, the anti-inflammatory and anti-oxidation functions are remarkably improved after being coupled with the polypeptide, targeted delivery is achieved, and the residence time is prolonged; the introduction of the tripeptide ACE simulating the function of glutathione further enhances the oxidative stress resistance of the conjugate. Furthermore, the conjugate shows excellent anti-inflammatory and anti-oxidation effects, can clear ROS, inhibit inflammation pathways, regulate macrophage phenotypes and inhibit apoptosis, and provides a new strategy for treatment of atherosclerosis.

The invention discloses an atherosclerotic plaque risk assessment method and system based on artificial intelligence, relates to the technical field of medical image analysis, and provides the following scheme: synchronously acquiring medical image sequence and physiological signal time sequence data, generating a synchronization data set through time-space registration, and performing time-space registration on the synchronization data set; and inputting the synchronized data set into a pre-trained LSTM neural network, and outputting a dynamic artifact offset field which represents a displacement vector of a medical image pixel point along with a physiological signal phase. Gradient amplitude analysis is performed on the medical image sequence frame by frame to generate the gradient characteristic evolution graph, high, medium and low response areas are divided according to the dynamic gradient threshold interval, and the displacement correction vectors are configured for the areas, so that the problem of gradient response heterogeneity compensation deficiency in a conventional correction strategy is solved, adaptive deformation correction of an anatomical structure is realized, and the correction accuracy is improved. And low-gradient region structure dispersion and vascular wall edge sharpness attenuation caused by global compensation are inhibited.

Implemented is a catheter for removing material in a body lumen. The catheter includes a catheter tube, a flexible drive shaft, an infusion lumen, an extraction lumen, and a head configured to remove the material in the body lumen. The head includes a housing connected to the catheter tube. The housing includes an infusion aperture fluidly coupled to the infusion lumen, an extraction aperture fluidly coupled to the extraction lumen, and a cutting chamber having a cutout therein. The head further includes a balloon and a probe connected to and driven by the flexible drive shaft. The probe is disposed within the cutting chamber, and the probe is configured to remove the material from the body lumen, at the cutout, and pulverize the material within the cutting chamber.

The application discloses a method for constructing a mouse model of atherosclerosis induced without high-fat diet, and relates to the technical field of disease model construction.The mouse model construction method provided by the application obtains a mouse model that spontaneously exhibits atherosclerosis symptoms without high-fat diet induction.The mouse model of atherosclerosis induced without high-fat diet can be used for researching the pathogenesis of atherosclerosis and screening and evaluating drugs for atherosclerosis.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of FKBP10 in diagnosis and treatment of atherosclerosis. Specifically, the invention demonstrates that FKBP10 promotes the unique effect of EndMT in vascular pathology, which is associated with increasing the phenotypes of atherosclerosis and unstable plaques. The invention proves that FKBP10 promotes membrane localization of PARP1, activates PI3K / AKT and MAPK signal pathways, induces EndMT and promotes atherosclerosis and poor prognosis of patients. Meanwhile, EndMT is inhibited by screening a small molecule drug TAK733, and a new scheme is provided for clinical treatment of atherosclerosis, so that the application has good potential practical application value.

The invention relates to a preparation method and application of a probiotic-drug co-delivery oral self-emulsifying agent, which can effectively solve the problems of preparation of the probiotic-drug co-delivery oral self-emulsifying agent and application of the probiotic-drug co-delivery oral self-emulsifying agent in drugs for treating atherosclerosis. Span80 and Cremophor RH40 are used as a compound emulsifier, PEG400 is used as a co-emulsifier, Res is used as a model drug, L.P resuspended by skim milk powder is used as an internal water phase, FA is used as a target head, a water-in-oil type targeted self-emulsifying preparation is constructed, after the water-in-oil type targeted self-emulsifying preparation is orally taken into an intestinal tract, the water-in-oil type targeted self-emulsifying preparation can be subjected to self-emulsifying phase inversion to form an oil-in-water type nano-emulsion, lactobacillus plantarum of the internal water phase is released and colonized in a gastrointestinal tract, different targets are co-delivered, synergistic interaction is achieved, and the water-in-oil type targeted self-emulsifying preparation is prepared. The preparation method is simple, production and preparation are easy, the biocompatibility is good, the medicine is an innovation in the aspect of medicine for treating atherosclerosis, and the economic and social benefits are remarkable.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., Alzheimer's disease, atherosclerosis, or inflammation of the choroid plexus (ChP).

The present invention relates to the field of traditional Chinese medicine technology, and in particular to a Chinese medicine composition, granule preparation and preparation method thereof for treating carotid atherosclerosis combined with hyperlipidemia. The Chinese medicine composition for treating carotid atherosclerosis combined with hyperlipidemia is mainly prepared from the following components in parts by weight: 8-12 parts of Chuanxiong, 8-12 parts of red peony root, 3-7 parts of coptis root, 8-12 parts of red yeast rice and 3-7 parts of roasted liquorice. The Chinese medicine composition provided by the present invention can have good therapeutic effects on the patient group with carotid atherosclerosis combined with hyperlipidemia, which is a common and frequently occurring disease in the field of cardiovascular disease prevention and treatment. In addition, the present invention prepares the Chinese medicine composition into a granule preparation in a certain manner, ensuring the molding rate, solubility rate, bulk density, angle of repose and moisture absorption rate of the preparation, thereby ensuring the efficacy of the preparation, extending the storage time of the product, taking into account the patient's acceptance, and easily realizing large-scale production.

The invention discloses a lipid droplet specific fluorescent probe as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention provides a structural formula of the lipid droplet specific fluorescent probe, and during preparation, 2-formaldehyde-6-(diethylamino) benzo [B] furan and a malononitrile derivative are used for preparing a fluorescent probe with an extended pi conjugated system under the action of an alkali environment; the fluorescent probe has the characteristic of intramolecular charge transfer (TICT), fluorescence in an aqueous solution is extremely weak, fluorescence in sunflower seed oil is remarkably enhanced, and the fluorescent probe has remarkable Stokes shift, excellent biocompatibility, excellent light stability and high signal-to-noise ratio. Meanwhile, the fluorescent probe shows extremely high sensitivity and signal-to-noise ratio in the aspect of cell lipid droplet imaging, and dynamic and accurate targeted imaging of lipid droplets can be easily realized. Therefore, the fluorescent probe disclosed by the invention is expected to become an alternative scheme for accurate detection of atherosclerosis.

Rotational atherectomy devices and systems can remove or reduce stenotic lesions in blood vessels by rotating an abrasive element within the vessel. The abrasive element can be attached to a distal portion of an elongate flexible drive shaft that extends from a handle assembly.

The invention discloses a bionic carrier-free nano-drug coated with a macrophage membrane as well as a preparation method and application of the bionic carrier-free nano-drug. The preparation method of the bionic carrier-free nano-drug comprises the following steps: S1, preparing PR-coated PBNPs: preparing a carrier-free self-assembled nano-drug PR-coated PBNPs from puerarin PR and probucol PB by adopting a nano-precipitation method; and S2, preparing MPR (at) PBNPs: coating the surface of the PR (at) PBNPs with a macrophage membrane, so as to obtain the bionic carrier-free nano-drug MPR (at) PBNPs. According to the nano-drug disclosed by the invention, due to the coating of a macrophage membrane, MPR-coated PBNPs can be promoted to be enriched to an AS diseased region; in the plaque region, the MPR-coated PBNPs releases PR and PB drugs, so that the oxidative stress and apoptosis of endothelium and macrophages are effectively relieved; in addition, endothelial cells can be inhibited from absorbing lipid and foam macrophages can be prevented from being formed, so that the atherosclerosis can be efficiently and safely treated.

The present disclosure relates to anti-human CD154 antibodies having a modified effector function. The present disclosure also relates to the use of these anti-human CD154 antibodies in the treatment of conditions associated with CD154 activation, the conditions associated with CD154 activation are, for example, transplant rejection, inflammatory conditions and diseases, dysfunctional immune responses associated with viral infections and diseases, autoimmune conditions and diseases, allergic conditions, atherosclerotic conditions, or neurodegenerative conditions and diseases. The present disclosure also relates to the use of these anti-human CD154 antibodies in inducing central tolerance and hematopoietic cell chimerism in transplanted patients.

Compositions and method of increasing levels of apoA1 and / HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and / or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and / or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and / or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

Provided herein are engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating atherosclerosis-related autoimmune disease, and chimeric antigen receptor expressing T cell (CAR-T) comprising a beta chain CDR3 selected from the amino acid sequence of SEQ ID NOS: 179 to 356 and an alpha chain, wherein the TCR is specific for a human apolipoprotein B (ApoB) epitope, antigen-MHC binding portions, and full-length versions of the same.